Neovacs Valuation

Is 0W8U undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0W8U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0W8U's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0W8U's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0W8U?

Key metric: As 0W8U is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0W8U. This is calculated by dividing 0W8U's market cap by their current revenue.
What is 0W8U's PS Ratio?
PS Ratio	0.2x
Sales	€538.29k
Market Cap	€87.92k

0W8U key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0W8U's PS Ratio compare to its peers?

The above table shows the PS ratio for 0W8U vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	12.5x
TCF Theracryf	5.8x	-150.1%	UK£2.3m
BSFA BSF Enterprise	44.2x	n/a	UK£3.0m
TCON TRACON Pharmaceuticals	0.03x	n/a	US$107.5k
OBSN ObsEva	0.008x	n/a	CHF 140.6k
0W8U Neovacs	0.2x	n/a	€87.9k

Price-To-Sales vs Peers: 0W8U is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (10.6x).

Price to Sales Ratio vs Industry

How does 0W8U's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.1x	19.4%
0W8U Neovacs	0.2x	n/a	US$94.65k
GNS Genus	1.7x	3.5%	US$1.41b
OXB Oxford Biomedica	4.5x	21.0%	US$554.49m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	8.1x	37.0%
0W8U Neovacs	0.2x	n/a	US$94.65k

No more companies

Price-To-Sales vs Industry: 0W8U is good value based on its Price-To-Sales Ratio (0.2x) compared to the UK Biotechs industry average (20.9x).

Price to Sales Ratio vs Fair Ratio

What is 0W8U's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0W8U PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0W8U's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.5%

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

4.0%

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

-1.7%

-6.3%